# BPC-157 Legal Status: FDA 503A Category and Compounding Access > BPC-157 legal status, the FDA 503A category, and how compounding access works: BPC-157 is in 503A Category 2 (effective 2023-09-29) and is on the July 2026 PCAC agenda as a substance under evaluation — a scheduled discussion, not a decision. The forward-leaning fact and the present-tense fact, kept distinct: access is under active FDA review and may expand in 2026 — and BPC-157 stands in 503A Category 2 today. ## Why the BPC-157 legal status is worth reading closely now The BPC-157 legal status is in motion, and the forward-leaning fact is genuine: BPC-157 is individually named on the published agenda of the FDA Pharmacy Compounding Advisory Committee (PCAC) meeting scheduled for July 23-24, 2026, as a bulk drug substance "being considered for inclusion on the 503A Bulks List" — the same agenda also lists KPV, TB-500, and MOTs-C [19]. In that precise sense, compounded access to BPC-157 is under active FDA review and may expand in 2026. That momentum is worth stating plainly, and being exact about what it is not is just as important. A PCAC agenda item is a scheduled evaluation and discussion. It is not a listing decision, not a reclassification, and not a change in the substance's current status — and a PCAC discussion is advisory, so no outcome should be assumed or dated [19]. The honest reading is two coordinates held apart: where the record is heading, and where it stands today. ## The current FDA fact, stated present-tense Today, BPC-157 is a research peptide that FDA placed in 503A "Category 2" — bulk substances that FDA identified as possibly presenting significant safety risks. The placement took effect with FDA's September 29, 2023 update to the list of bulk drug substances nominated for use under section 503A, and FDA evaluated the entries listed as "BPC-157 (free base)" and "BPC-157 acetate" [16]. FDA's stated rationale included concerns about potential immunogenicity for certain routes of administration and complexities with peptide-related impurities and active-ingredient characterization [16]. Two consequences follow directly. Because Category 2 substances are not covered by FDA's enforcement-discretion policy for 503A compounding, BPC-157 is not within that policy while this status stands. And separately, BPC-157 is not an FDA-approved drug — approval of a finished drug is a different question from whether a bulk substance may be used in compounding, and BPC-157 has cleared neither bar [16]. It is also prohibited in sport at all times by the World Anti-Doping Agency under the S0 non-approved-substances category [18]. ## How the 503A and 503B framework works Two sections of the Federal Food, Drug, and Cosmetic Act govern compounding. Section 503A covers traditional, patient-specific compounding by state-licensed pharmacies and physicians, generally pursuant to a valid prescription for an individual patient. Section 503B covers FDA-registered "outsourcing facilities" that may compound larger batches under cGMP-style oversight and FDA inspection [16]. The constraint that matters for BPC-157 is the ingredient rule. A compounder may use a bulk drug substance — an active ingredient used as a starting material, rather than an FDA-approved finished drug — only if that substance has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on FDA's 503A bulks list. Substances not yet on a bulks list are evaluated by FDA through a public nomination process with input from PCAC; being discussed by PCAC is a step in that evaluation, not a final listing decision [16][19]. This is the precise mechanism by which the July 2026 meeting could, in principle, matter — and the precise reason it has not yet changed anything. ## What this means for compounded access In general terms, a legally compounded medication in the U.S. is prepared only after an individual patient is evaluated by an appropriately licensed prescriber who determines a compounded preparation is clinically appropriate and issues a valid, patient-specific prescription. The preparation is then made by a state-licensed 503A compounding pharmacy or, for larger volumes, sourced from an FDA-registered 503B outsourcing facility [16]. Telehealth can serve as the front-end channel for the prescriber-evaluation step — a route to a licensed-prescriber consultation and prescription. It does not change which substances are eligible to be compounded, and it does not remove the need for a legitimate clinical evaluation and a valid prescription [16]. The ingredient-eligibility caveat is the binding one: a compounder may use a requested active ingredient only if that ingredient is eligible under the 503A/503B bulk-substance rules, and a substance FDA has flagged for significant safety risks is not eligible for routine 503A compounding while that status stands [16]. For BPC-157, that is the current state of the record. This page is general information about the regulatory landscape. It is not medical or legal advice, it does not name or recommend any pharmacy, clinic, or telehealth provider, and it is not an offer to sell or supply any substance. --- A cobalt-blueprint reading of the BPC-157 record — every finding plotted to its study, the human-data gap left as an open cell, and the FDA 503A status struck before anything else; no clinic at the bench and nothing here dispensed or sold.